Physician profile
Drew David Howard
NPI 1366530750
$10,809.29
in general payments reported to CMS, 2019-2025
22 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $181 · 2021: $6,268 · 2022: $666 · 2023: $1,873 · 2024: $1,215 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,845 · Food and Beverage: $1,394 · Education: $42.03 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,845.06 |
| Food and Beverage | $1,394.09 |
| Education | $42.03 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,631.76 | 2021-2024 | Da Vinci Surgical System |
| Ethicon US, LLC | $634.28 | 2019-2025 | Stratafix, Echelon Flex, Ethicon |
| Baxter Healthcare | $355.59 | 2020-2024 | Tisseel |
| Medtronic, INC. | $326.62 | 2022-2024 | Situate, Sonicision, Endoflip |
| Stryker Corporation | $162.09 | 2019 | |
| Tela Bio, INC. | $123.38 | 2021-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Allergan, INC. | $100.95 | 2020-2022 | |
| Davol INC. | $99.83 | 2021-2025 | Phasix Mesh |
| Vertex Pharmaceuticals Incorporated | $72.41 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $54.44 | 2023-2024 | Exparel |
| Apollo Endosurgery US INC | $34.48 | 2021 | |
| Boston Scientific Corporation | $28.64 | 2025 | Spyglass Discover |
| Conmed Corporation | $28.19 | 2021 | |
| Avita Medical Americas, LLC | $26.32 | 2025 | Cohealyx, Recell, Permeaderm |
| Shionogi INC | $23.37 | 2023 | Fetroja |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $20.17 | 2025 | Aponvie |
| Takeda Pharmaceuticals U.S.A., INC. | $16.86 | 2022 | |
| Innocoll Pharmaceuticals Limited | $16.28 | 2022 | |
| Tei Biosciences INC | $15.95 | 2019 | |
| Standard Bariatrics, INC. | $12.58 | 2022 | |
| Redhill Biopharma INC. | $12.57 | 2021 | |
| Coopersurgical, INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.